Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Natco Pharma
30 Capsules
Lenalidomide
Keep in cold place
Delivering To:
Overview
Lenalid 10mg Capsule is used in the treatment of multiple myeloma, a type of blood cancer. It enhances the immune system, which indirectly attacks the cancer cells. Lenalid 10mg Capsule prevents the growth of new blood vessels within the tumor. Lenalid works by restricting the production of chemical messengers (cytokine and growth factor) which are responsible for the growth of cancer cells.
Multiple myeloma
Multiple myeloma
Treatment of Myelodysplastic Syndrome
Most side effects of Lenalid 10mg Capsule do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.
Cough
Nausea
Sore throat
Vomiting
Weakness
Dizziness
Fever Decrease in white blood cell count
Sleepiness
Confusion
Tremor
Swelling
Respiratory disorder
Bleeding gums
Blood clots
Decreased calcium level in the blood
Follow your doctor's instructions on the dosage and duration of this medication. It is preferable to take Lenalid 10 Capsule at specific times, but it can be taken with or without food.
Lenalid 10mg Capsule, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties. Lenalidomide works to inhibit the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalid 10mg inhibits cell proliferation with varying effectiveness (IC50s) in some but not all cell lines. Lenalid 10mg Capsule is effective in inhibiting the growth of Namalwa cells (a human B cell lymphoma cell line with a deletion of one chromosome 5) but is much less effective in inhibiting the growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 5) and other cell lines without chromosome 5 deletions. It does not prolong the QTc interval.
Alcohol
unsafe
It is advisable not to consume alcohol while taking medicine.
Pregnancy
consult your doctor
Do not take Lenalid 10mg Capsule without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Lenalid 10mg Capsule without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
If you forget to take a dose of Lenalid Capsule, consult your doctor. Don’t double up the next dose to cope with the missed one unless your doctor recommends it.
Lenalid Capsule is used in the treatment of multiple myeloma and lepra reactions.
Please contact your healthcare provider for the details of the required dose.
The side effects are cough, nausea, vomiting, fever, sore throat, anxiety, muscle pain, constipation, and sleepiness. Please consult your healthcare provider if you experience these or any other side effects.
You may feel sleepy or dizzy after taking Lenalid 10mg. Therefore, it is advised not to drive or operate machinery.
No, the use of Lenalid is not effective in mental disorders.
Lenalid 10mg Capsule is a member of the immunomodulatory agent drug class.
During treatment and for seven days following treatment completion, individuals using Lenalid 10mg Capsule are not allowed to donate blood. Pregnant women may get donated blood, which could result in severe birth defects.
Chen, N., Zhou, S., Palmisano, M. (2017). Clinical pharmacokinetics and Pharmacodynamics of lenalidomide. Clinical Pharmacokinetics, 56(2), 139–152. Monteiro, M. M., Ferreira, F. V., Santos, J. P., Lima, J. A., & de Almeida, M. F. (2023). Bioequivalence of lenalidomide 10 mg capsule (Eurofarma Laboratórios S/A) to Revlimid® 10 mg under fasting conditions in healthy subjects. Brazilian Journal of Pharmaceutical Sciences, 59 Preston, S., Anderson, N. E., Basile, V. S., Holton, T., Schmid, K., Graham, A., Fok, A., Taylor, A., & Taylor, B. V. (2024). A phase 1b, dose-finding Study of lenalidomide in patients with anti-MAG neuropathy: Safety, tolerability, and maximum tolerated dose. European Journal of Neurology, 31(3), 560–568.
Syed, S., Esseltine, D. L., Reeves, J., Abolhassani, S., Akhter, A., Sarin, N., Lozanski, G., Benson, D. M., Baiocchi, R. A., & Hofmeister, C. C. (2024). A Phase I trial evaluating the addition of lenalidomide to ruxolitinib and methylprednisolone in patients with relapsed or refractory multiple myeloma. Blood, 142(Supplement 1), 4753–4753.
Washington University School of Medicine. (2025). Lenalidomide treatment for inflammation and cognition in early Alzheimer’s disease [Interventional clinical trial protocol]. ClinicalTrials.gov.
